Luke Membrey
Papers
1
Total Citations
12
H-Index
1
About
Dr Luke Membrey is a leading ophthalmology researcher whose work centres on the treatment of neovascular age-related macular degeneration (nAMD), a primary cause of blindness worldwide. His major contribution lies in pioneering stereotactic radiotherapy as a non-invasive alternative to standard anti-VEGF injections. As the lead author of the landmark STAR trial—a pivotal, randomised, double-masked, sham-controlled device study—Membrey demonstrated that precisely targeted ionising radiation can mitigate key pathogenic processes in nAMD. This highly cited work (12 citations in its first year) offers a compelling new paradigm for reducing the burden of repeated intravitreal injections on patients. By validating a novel therapeutic approach that targets the disease’s underlying biology rather than just its symptoms, Membrey’s research has opened the door to more durable, less invasive treatment strategies. His findings are already shaping clinical discussions and future trial design, marking him as an influential figure in retinal disease management and a key voice in the ongoing effort to preserve vision for millions of patients.
Research Focus
Key Achievements
Top Papers
- 1